The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
30 October 2026 With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.
13 October 2026 Potential reforms to post-employment restrictions and contractual notice periods could make it harder for brand owners to protect trade secrets and manage staff departures, prompting questions about how businesses can safeguard their interests.
9 October 2026 As the AIPPI World Congress returned to Germany for the first time in nearly half a century, it heard calls for greater international cooperation and legal harmonisation, highlighting why diversity matters for the future of IP and brand owners.